{"disease":{"id":"diabetes-mellitus-type-1","name":"Diabetes mellitus type 1","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"dapagliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"insulin-glargine","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lantus","generic_name":"INSULIN GLARGINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"4800","mechanism":"Lantus works by mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"insulin-lispro","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humalog","generic_name":"INSULIN LISPRO","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"2200","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream."},{"drug_id":"lantus","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lantus","company_name":"Rijnstate Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"lyumjev","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lyumjev","company_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"teplizumab-mzwv","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TZIELD","generic_name":"TEPLIZUMAB-MZWV","company_name":"PROVENTION BIO INC","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3-directed Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"dapa","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"insulin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humulin","generic_name":"insulin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"Insulin Analog [EPC]","quality_score":60,"revenue":null,"mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels."},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"forxiga","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"ipragliflozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suglat","generic_name":"IPRAGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"humalog","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humalog","company_name":"Halozyme Therapeutics","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dapaglifozin","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"teplizumab","indication_name":"Diabetes mellitus type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tzield","generic_name":"TEPLIZUMAB","company_name":"Provention Bio Inc","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Tzield works by binding to the CD3 complex on T-cells, preventing them from attacking pancreatic beta cells."}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03811470","title":"China Diabetes Registry by Metabolic Management Center","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Guang Ning","has_results":false},{"nct_id":"NCT00097292","title":"TrialNet Pathway to Prevention of T1D","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT04629586","title":"The T1D Exchange Registry","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"T1D Exchange, United States","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT01696266","title":"An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":29304,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06573905","title":"Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":17271,"lead_sponsor_name":"Universite du Quebec en Outaouais","has_results":false},{"nct_id":"NCT03503747","title":"Investigating Genetic Risk for Type 1 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":15640,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04657783","title":"French National Cohort of People With Type 1 Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Fondation Francophone pour la Recherche sur le Diabete","has_results":false},{"nct_id":"NCT06280729","title":"AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT02306681","title":"A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":7315,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01984372","title":"Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®","phase":"","overall_status":"COMPLETED","enrollment_count":6163,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT00179777","title":"TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk","phase":"NA","overall_status":"COMPLETED","enrollment_count":5156,"lead_sponsor_name":"University of Helsinki","has_results":true},{"nct_id":"NCT04327622","title":"Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population","phase":"","overall_status":"COMPLETED","enrollment_count":5084,"lead_sponsor_name":"LMC Diabetes & Endocrinology Ltd.","has_results":false},{"nct_id":"NCT03988764","title":"Monogenic Diabetes Misdiagnosed as Type 1","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT05348551","title":"Overview of Telemedicine in Children With Type 1 Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":4800,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT02973412","title":"Chronotype of Patients With Diabetes and Effect on Glycaemic Control","phase":"","overall_status":"RECRUITING","enrollment_count":3447,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT04503174","title":"Control-IQ Observational (CLIO) Post-Approval Study","phase":"","overall_status":"COMPLETED","enrollment_count":3157,"lead_sponsor_name":"Tandem Diabetes Care, Inc.","has_results":true},{"nct_id":"NCT04201171","title":"The Impact of Different CSII and CGM Systems on Different Clinical Outcome Variables in Children and Adolescents With Type 1 Diabetes. An Observational Study Form the Norwegian Childhood Diabetes Registry (NCDR)","phase":"","overall_status":"COMPLETED","enrollment_count":2749,"lead_sponsor_name":"Helse Fonna","has_results":false},{"nct_id":"NCT01892319","title":"An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2446,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02662114","title":"Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":2302,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06115876","title":"Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Dasman Diabetes Institute","has_results":false},{"nct_id":"NCT01492153","title":"NovoLet® Surveillance Study on Using Human Insulin System in Indonesia","phase":"","overall_status":"COMPLETED","enrollment_count":1981,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07212075","title":"Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","phase":"","overall_status":"RECRUITING","enrollment_count":1809,"lead_sponsor_name":"Forschungsinstitut der Diabetes Akademie Mergentheim","has_results":false},{"nct_id":"NCT01492218","title":"Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction","phase":"","overall_status":"COMPLETED","enrollment_count":1330,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01831765","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1290,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT04270604","title":"Biological Sample Collection for Research and Biobanking","phase":"","overall_status":"TERMINATED","enrollment_count":1279,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT02392117","title":"Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":1262,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03838900","title":"The Loop Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":1212,"lead_sponsor_name":"Jaeb Center for Health Research","has_results":false},{"nct_id":"NCT04219514","title":"Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models","phase":"","overall_status":"COMPLETED","enrollment_count":1206,"lead_sponsor_name":"Stewart Harris","has_results":false},{"nct_id":"NCT06931275","title":"Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes","phase":"NA","overall_status":"RECRUITING","enrollment_count":1178,"lead_sponsor_name":"T1D Exchange, United States","has_results":false},{"nct_id":"NCT04414280","title":"The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1150,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT02500706","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1108,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT02117622","title":"A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India","phase":"","overall_status":"COMPLETED","enrollment_count":1056,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03364868","title":"GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1050,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT03489031","title":"Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient.","phase":"","overall_status":"COMPLETED","enrollment_count":1036,"lead_sponsor_name":"Associazione Medici Endocrinologi","has_results":false},{"nct_id":"NCT01492959","title":"Observational Study With InnoLet® in Daily Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02230618","title":"Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India","phase":"","overall_status":"COMPLETED","enrollment_count":1029,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05234281","title":"Concentrated Cross-disciplinary Group Intervention for Common Health Complaints (Including Post COVID-19 Fatigue)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Helse i Hardanger","has_results":false},{"nct_id":"NCT02580591","title":"Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":977,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT07076199","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":877,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02670915","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":834,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT06317454","title":"Determinants of Metabolic Control in Children With Type 1 Diabetes Mellitus","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"IRCCS Burlo Garofolo","has_results":false},{"nct_id":"NCT06325111","title":"Determinants of Glycaemic Control in Children With Type 1 Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"IRCCS Burlo Garofolo","has_results":false},{"nct_id":"NCT03607604","title":"Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE","phase":"","overall_status":"UNKNOWN","enrollment_count":778,"lead_sponsor_name":"Imperial College London Diabetes Centre","has_results":false},{"nct_id":"NCT04311164","title":"Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":770,"lead_sponsor_name":"Steno Diabetes Center Copenhagen","has_results":false},{"nct_id":"NCT03416855","title":"A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":768,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03220425","title":"Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02414958","title":"Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":730,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03674866","title":"A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":50},"guidelines":[{"drug_id":"insulin","guideline_body":"FDA label","recommendation":"ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"insulin","guideline_body":"FDA label","recommendation":"ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}